Recommended Terms and Definitions From the 2025 NCCN Biomarkers Resource Committee
Journal of the National Comprehensive Cancer Network · 2026
DOI: 10.6004/jnccn.2026.7021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026. Verfasst von Melissa Y Tjota und 11 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Pathology, University of Chicago Medicine, Chicago, IL. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Terminology as Topic, Neoplasms, Medical Oncology. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
The NCCN Biomarkers Resource Committee (BRC) was established to provide molecular expertise and guidance related to key aspects of biomarker testing in NCCN publications. A key aim is to reduce inconsistencies and standardize biomarker testing terms and definitions for suggested use across all NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). The key areas found to need terminology clarification and harmonization included those describing types of genomic events and testing approaches. For these areas, current professional society guidelines regarding terminology, utilization within current guidelines, and common parlance in practice were explored. Synonyms were also identified. Each area was discussed to nominate preferred (and, when applicable, nonpreferred) terminology with a rationale. The aims of this document are to define commonly used terms for clinical care providers and provide recommendations for the standardized use of this biomarker terminology within NCCN Guidelines and publications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Department of Pathology, University of Chicago Medicine, Chicago, IL.
- 2Department of Medical and Molecular Genetics, and IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IL.
- 3Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL.
- 4Department of Pathology, Stanford Health Care, Stanford, CA.
- 5Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- 6Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Zitieren
APA
Tjota, M. Y., Hodge, J. C., Jennings, L. J., Allison, K., Dogan, A., Lotan, T. L., Nardi, V., Pal, T., Ostanina, S., Birkeland, M. L., Aisner, D. L., & Dong, F. (2026). Recommended Terms and Definitions From the 2025 NCCN Biomarkers Resource Committee. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2026.7021
Vancouver
Tjota MY, Hodge JC, Jennings LJ, Allison K, Dogan A, Lotan TL, et al. Recommended Terms and Definitions From the 2025 NCCN Biomarkers Resource Committee. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2026.7021
BibTeX
@article{Tjota2026,
author = {Tjota, Melissa Y and Hodge, Jennelle C and Jennings, Lawrence J and Allison, Kimberly and Dogan, Ahmet and Lotan, Tamara L and Nardi, Valentina and Pal, Tuya and Ostanina, Svitlana and Birkeland, Marian L and Aisner, Dara L and Dong, Fei},
title = {Recommended Terms and Definitions From the 2025 NCCN Biomarkers Resource Committee},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
doi = {10.6004/jnccn.2026.7021}
}
EUVIMED